Rafei Hind, El-Bahesh Ehab, Finianos Antoine, Liu Min-Ling L, Schechter Geraldine P
Division of Internal Medicine of the Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Division of Hematology Oncology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Case Rep Hematol. 2017;2017:9561013. doi: 10.1155/2017/9561013. Epub 2017 Sep 24.
. Plasmablastic lymphoma (PBL) is a rare and highly aggressive variant of diffuse large B cell lymphoma with median survival of advanced stage patients varying between 6 and 15 months in previous reports. We report here a human immunodeficiency virus-infected patient surviving over 12 years following treatment for advanced PBL with EPOCH chemotherapy and intrathecal therapy. This case highlights the potential for improved survival in PBL with intensive chemotherapy. Further, literature review suggests promising prospects utilizing novel targeted therapies to increase the rate of prolonged responses.
浆母细胞淋巴瘤(PBL)是弥漫性大B细胞淋巴瘤的一种罕见且高度侵袭性的变异型,既往报道中晚期患者的中位生存期在6至15个月之间。我们在此报告一例人类免疫缺陷病毒感染患者,在接受EPOCH化疗和鞘内治疗后,晚期PBL存活超过12年。该病例凸显了强化化疗改善PBL患者生存的潜力。此外,文献综述表明,利用新型靶向治疗有望提高长期缓解率。